secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2022-02-08T23:59:59+00:00
Accession:  0001493152-22-003481
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences appoints Lee Rauch to board of directors
------------------------------------------------------------

- Lee Rauch appointed as Class I director effective Feb 8, 2022; term expires at 2022 annual meeting.
- Rauch will serve on Compensation Committee; granted option for 20,000 shares at $1.70 per share.
- Receives annual cash compensation of $7,500, prorated for service through the 2022 annual meeting.
- Rauch is a 40-year industry veteran, former CEO of Viridian Therapeutics and founding member of McKinsey's pharma practice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315222003481/0001493152-22-003481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315222003481/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-003481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer